Infantile hemangioma (IH) is the most common benign vascular tumor seen in childhood. After an early proliferative phase in the first weeks of life, the majority of hemangiomas complete their growth and start to involute by approximately 12 months.

Undiagnosed bleeding disorders put people at risk due to bleeding without an optimal treatment strategy. Spanish researchers from the Hospital Universitario La Paz and Universidad Autónoma de Madrid have focused on the targeting of tissue factor pathway inhibitor (TFPI) as a potential approach for this medical need by using TFPI blocker antibodies.